Beta Bionics (NASDAQ:BBNX) Stock: Insider Mark Hopman Sells 775 Shares

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mark Hopman sold 775 shares of the business’s stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $17.35, for a total transaction of $13,446.25. Following the transaction, the insider directly owned 55,334 shares in the company, valued at approximately $960,044.90. The trade was a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Mark Hopman also recently made the following trade(s):

• On Thursday, October 1st, Mark Hopman sold 370 shares of Beta Bionics stock. The shares were sold at an average price of $18.96, for a total transaction of $7,015.20.
• On Wednesday, September 16th, Mark Hopman sold 30,779 shares of Beta Bionics stock. The shares were sold at an average price of $20.13, for a total transaction of $619,581.27.
• On Wednesday, September 9th, Mark Hopman sold 36,870 shares of Beta Bionics stock. The stock was sold at an average price of $18.46, for a total transaction of $680,620.20.
• On Wednesday, September 2nd, Mark Hopman sold 5,327 shares of Beta Bionics stock. The stock was sold at an average price of $19.11, for a total transaction of $101,798.97.

Beta Bionics Price Performance

Shares of BBNX stock opened at $16.35 on Friday. Beta Bionics, Inc. has a 12 month low of $8.80 and a 12 month high of $32.71. The firm has a market capitalization of $735.59 million, a P/E ratio of -9.91 and a beta of 3.39. The company’s fifty day moving average price is $19.04 and its two-hundred day moving average price is $15.19.

Beta Bionics (NASDAQ:BBNX) last posted its quarterly earnings data on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. The company had revenue of $32.01 million during the quarter. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. On average, sell-side analysts anticipate that Beta Bionics, Inc. will post -2.02 EPS for the current year.

Trending Headlines about Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Negative Sentiment: The securities lawsuit covers investors who purchased Beta Bionics shares between July 30, 2025, and February 24, 2026. The claims reportedly relate to alleged disclosures concerning the FDA’s concerns about the company’s iLet automated insulin-delivery system and the impact of those revelations on the stock. The allegations have not been proven. Hagens Berman securities class-action announcement
• Negative Sentiment: Additional notices cite allegations that Beta Bionics abandoned a safety feature in the iLet dosing algorithm and failed to investigate more than 18,000 customer complaints. If substantiated, such claims could increase regulatory, litigation, and reputational risks for the company. SueWallSt Beta Bionics lawsuit notice
• Negative Sentiment: The high volume of investor-law-firm announcements keeps attention focused on legal exposure and prior share-price losses, weighing on investor confidence. The lead-plaintiff deadline is November 3, 2026. Kaplan Fox lead-plaintiff deadline notice
• Neutral Sentiment: Insider Mark Hopman sold 775 shares for approximately $13,446, reducing his direct ownership by 1.38%. Because the sale was small relative to his remaining 55,334 shares, it is a modest signal but may add some pressure to sentiment. SEC insider transaction filing

Wall Street Analysts Forecast Growth

BBNX has been the subject of a number of recent analyst reports. Robert W. Baird raised their price objective on Beta Bionics from $14.00 to $16.00 and gave the company a “neutral” rating in a research note on Tuesday, September 15th. UBS Group restated a “buy” rating and set a $25.00 price objective on shares of Beta Bionics in a report on Tuesday, September 15th. Wells Fargo & Company assumed coverage on Beta Bionics in a research report on Wednesday, September 23rd. They issued an “overweight” rating and a $28.00 target price on the stock. Truist Financial upped their target price on Beta Bionics from $23.00 to $28.00 and gave the company a “buy” rating in a research report on Thursday, September 24th. Finally, Wall Street Zen upgraded Beta Bionics from a “sell” rating to a “hold” rating in a research note on Saturday, September 19th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Beta Bionics presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in shares of Beta Bionics in the 2nd quarter valued at about $52,340,000. Eversept Partners LP lifted its position in shares of Beta Bionics by 108.6% during the first quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock worth $14,177,000 after purchasing an additional 736,576 shares during the last quarter. 12 West Capital Management LP acquired a new position in Beta Bionics in the fourth quarter worth about $17,520,000. Bruce & Co. Inc. acquired a new position in Beta Bionics in the first quarter worth about $5,518,000. Finally, Bank of America Corp DE acquired a new position in Beta Bionics in the second quarter worth about $8,566,000.

About Beta Bionics

Beta Bionics, Inc is a medical technology company focused on developing and commercializing automated insulin delivery systems for people with insulin-requiring diabetes. Its lead product is the iLet Bionic Pancreas, an insulin pump system designed to automate much of the insulin-dosing process and reduce the daily burden associated with diabetes management.

The iLet Bionic Pancreas uses continuous glucose monitoring data and the company’s dosing algorithms to deliver insulin. Unlike conventional insulin pumps that generally require users to calculate meal doses, the system is designed to simplify mealtime dosing by using a person’s body weight and meal announcements as key inputs.